Active process to nullify rapidly-grown ‘Eiliquis’ & ‘Pradaxa’ patents

Domestic pharmaceutical companies will challenge the patent wall of novel oral anticoagulants(NOACs), ‘Pradaxa’ and ‘Eliquis.’ They are also trying to nullify the ‘Brilinta’ patent as well.

According to the pharmaceutical industry and the Intellectual Property Tribunal on the 6^th, Korean pharmaceutical companies recently challenged to patents of Pradaxa, Eliquis and Brilinta. Since the challen...